PRINCETON, N.J., July 20, 2026
Bristol Myers Squibb (BMS) announced a major expansion of its strategic collaboration with NVIDIA by deploying a next-generation NVIDIA DGX SuperPOD powered by DGX Vera Rubin NVL72 systems, creating what the company describes as the most powerful and energy-efficient single-owned NVIDIA AI infrastructure in the life sciences industry. The investment significantly strengthens BMS’s artificial intelligence capabilities, enabling researchers to train larger proprietary AI foundation models, accelerate drug discovery, and advance its long-term vision of hybrid intelligence, where AI scientists work alongside human researchers to develop first- and best-in-class medicines. The expanded computing platform will support research across oncology, hematology, cardiovascular disease, immunology, and neuroscience, providing the computational scale needed to analyze increasingly complex biological datasets while reducing research timelines and improving scientific decision-making.
Next-Generation AI Infrastructure Powers Advanced Drug Discovery
The newly deployed NVIDIA DGX Vera Rubin NVL72 architecture delivers a significant leap in computational performance and efficiency, offering up to ten times greater performance per megawatt compared with previous-generation systems. This enables Bristol Myers Squibb to execute substantially larger AI workloads without a proportional increase in energy consumption, supporting sustainable high-performance computing for pharmaceutical research. The infrastructure builds upon nearly three years of collaboration between BMS and NVIDIA, during which DGX SuperPOD systems have supported research and development programs. The latest expansion gives BMS scientists access to next-generation computing resources capable of processing massive biological datasets, accelerating AI model development, and supporting increasingly sophisticated machine learning applications throughout the drug discovery and development process.
Hybrid Intelligence Combines AI Scientists with Human Expertise
Bristol Myers Squibb is leveraging its enhanced AI platform to transform how medicines are discovered by integrating AI-powered scientific agents into every stage of research. The company’s AI systems already automate complex processes such as target identification and validation, reducing weeks of manual scientific work and allowing researchers to focus on experimental design and hypothesis testing. Through its “Predict First” strategy, AI-generated predictions now guide the design of every small molecule drug program and the majority of large molecule development programs, improving confidence before laboratory experiments begin. The new NVIDIA infrastructure will further enable development of proprietary foundation models trained on decades of BMS scientific data while incorporating specialized biological AI capabilities from NVIDIA BioNeMo to support agentic workflows that evaluate therapeutic hypotheses at unprecedented scale. This collaborative model positions AI as a scientific partner that performs data-intensive analysis while researchers concentrate on interpretation, innovation, and critical decision-making.
Advertisement
Strategic AI Investment Strengthens Future Pharmaceutical Innovation
The expanded collaboration reflects Bristol Myers Squibb’s broader strategy of embedding artificial intelligence across the entire drug development pipeline, from target discovery through clinical proof of concept. By continuously learning from experimental data and clinical outcomes, the company’s AI-powered research ecosystem aims to improve the probability of selecting successful therapeutic candidates while reducing development timelines. Company executives emphasized that the objective extends beyond accelerating research, focusing instead on improving scientific accuracy, reducing uncertainty, and increasing the likelihood of delivering innovative medicines to patients. As AI becomes an increasingly central component of pharmaceutical research, the deployment of one of the industry’s most advanced computing environments reinforces Bristol Myers Squibb’s position at the forefront of AI-enabled drug discovery, establishing a scalable platform capable of supporting next-generation biomedical innovation for years to come.
Source: Bristol Myers Squibb press release
